ABSTRACT
INTRODUCTION
Beta-thalassemias are hereditary and molecularly heterogeneous blood disorders. Insertions in the β-globin gene sequence, deletions or point mutations are molecular defects responsible for most β-thalassemia. Most patients come from Mediterranean countries and Middle East, South-East Europe, and Asia. Hematological changes can are detectable from between the ages of three months and six months onwards. Three main types of beta thalassemia are identified: thalassemia major, thalassemia intermedia and thalassemia minor. Individuals with thalassemia major usually present within the first two years of life with severe anemia, requiring regular blood transfusions [1, 2, 3] .
Elevated serum iron level and iron toxicity are among common complications in patients with thalassemia major who have frequent blood transfusion. If iron chelating approaches are neglected, the patient may encounter a variety of health problems, including diabetes mellitus [4, 5] . For thalassemia patients who have already suffered from morbidity, this problem is an extra burden and would further affect their life quality [6, 7, 8, 9] . Like other diabetic patients, diabetic patients with thalassemia must be continuously monitored for the progress of treatment and managing complication [10] .
Measurement of glycosylated hemoglobin (Hb) -also known as Hb A 1C -is a widespread method for estimation of blood glucose level in diabetic patients. Hb A 1C which is an extensively used marker in monitoring diabetes and management of the disease, is a glycosylated protein synthesized by binding of free amine group of glucose molecule to beta chain of globin protein through a two step reaction. In the first reversible step, a bond between free aldehyde group of glucose and amine group of the protein is formed. Subsequently, an intra-molecular rearrangement -known as Amadori reactionensues which results in formation of a stable ketoamine molecule. The reaction at this stage is irreversible. Bound glucose molecules would be removed from metabolism cycle and accumulated in circulating blood and increased by any prolongation in erythrocytes life span. Transitory changes in blood glucose level and sugar consumption prior to Hb A 1C test does not affect the result of examination. Average life span of erythrocytes is about 120 days and hence the amount of accumulated glycosylated Hb in blood may represent the available glucose concentration within the past 3 to 4 months. Existence of such relationship is confirmed by laboratory examinations and has become a basis for estimating mean plasma glucose concentration [11] . 1% change in Hb A 1C content is proportionate to 28 to 34 mg/dl change in blood glucose [12] . It is also demonstrated that health problems such as cerebral and cardio-renal dysfunctions affiliated with diabetes, are associated with high amount of this molecule [10] . Increased amount of Hb A 1C to 6% and higher, is a valuable marker in identifying diabetes mellitus patients. This method also helps identify asymptomatic patients, who previously had to be tested twice for fasting blood sugar or undergo glucose tolerance test [13] ; however there are some studies raising questions about credibility of measurement of Hb A 1C in estimating blood glucose storage in hemolytic patients and hemoglobinopathy carriers. In such cases measurement of fructosamine -another serum protein -as an alternative approach is suggested [14, 15, 16] .
Fructosamine (1-amino-1-dioxy-fructose) is a ketoamine and the product of non-enzymatic reaction of a carbohydrate (usually glucose) and a protein (generally albumin). Post synthesis, fructosamine undergoes non-enzymatic changes; this is a characteristic difference between fructosamine and glycoproteins [13, 14] . As glycation occurs during the whole course of serum protein life span, the amount of glycosylated proteins reflects the available quantity of blood sugar during this period. Measurement of these biochemical molecules is a reliable approach to estimate blood sugar level for a certain time window in diabetic patients. The quantity of available glycosylated albumin and fructosamine correlates to mean plasma glucose for the past one or two weeks, as half lives of plasma proteins are relatively short [17] .
The current study investigates the relationship between fructosamine and Hb A 1C and their correlation with plasma glucose content in thalassemia patients referred to thalassemia 
MATERIALS AND METHODS
This descriptive study was carried out in the summer of 2010. First, diabetes mellitus patients suffering from thalassemia major were selected and after receiving their consent, entered the study group. Medical history of patients was extracted from their records and peripheral blood samples were collected for laboratory examination.
Blood glucose concentration was measured via glucose oxidation based method by biochemistry auto-analyzer (Hitachi, Japan 
RESULTS
This study was carried out on 33 beta patients with thalassemia major, consisting of 21 female (63.6%) and 12 male (36.4%) cases, all suffering from diabetes. Patients were diagnosed with thalassemia at the average age of 1.5 years and with diabetes at the average age of 19.5 years. Mean age of diagnosis of diabetes in male cases was 21.2 years and in female patients 18.3 years. On average, it has been 7.8 years since patients were diagnosed with diabetes. Mean blood glucose levels in male and female patients were 224±101 mg/dL and 204±103 mg/dL respectively. The two values were not significantly different (p=0.63). Fetal Hb (Hb F) content were 13%±9% in male and 9%±7% in female patients (p=0.22); and serum ferritin levels were 3253±1773 ng/mL in males and 1744±1534 ng/mL in females (p=0.96). Mean serum fructosamine level in the whole group was 442±124 mmol/L and this value for Hb A 1C was 8.9%±1.8%. This amount for fructosamine in males was 450±116 mmol/L and 436±131 mmol/L in females, and for Hb A 1C it was 8.8%±1.8% in males and 9.0%±1.8% in females (table 1). 
DISCUSSION
The current study addresses an alternative methodology to evaluate blood glucose levels in patients afflicted by beta thalassemia major. The outcome showed that the two approaches -Hb A 1C and fructosamine -are both reliable in patients who have regular blood transfusion.
Using Hb A 1C to determine blood glucose level has its own limitations. Conditions that affect the rate of erythrocyte synthesis (hemolysis, bleeding) and presence of Hb variants may change the results. Such conditions must be particularly considered when Hb A 1C content is not compatible with patient's clinical symptoms [18] .
There have been several studies to evaluate the validity of the results of Hb A 1C in diabetic patients. Cohan and colleagues compared half life of erythrocytes and Hb A 1C content in diabetic patients and healthy people and showed erythrocyte life span in diabetic patients is reduced. This decrease, results in a meaningful reduction of Hb A 1C -compared to healthy population -affecting its linear correlation with blood glucose [19] ; however in another study on 371 diabetic patients, Guillausseau and colleagues showed a direct correlation between fasting blood sugar and the two markers: fructosamine and Hb A 1C . This study was followed up for 6 months and the results were reproducible [20] . In this study, the only clinical difference in interpreting the results of fructosamine and Hb A 1C was due to longer half life of Hb in comparison with other serum proteins and therefore in monitoring glucose level in diabetic patients it is better to use fructosamine test as a complimentary to Hb A 1C .
In a Study on 139 patients with diabetes mellitus, a linear correlation among blood glucose and the two markers Hb A 1C and fructosamine were found; however in that study, the results of Hb A 1C and fructosamine in 19 cases who were afflicted by thalassemia was not correlating with fasting blood sugar levels [21] . led to Hb A 1C of 1.6% despite high blood glucose level [23] .
Hb F encompasses half of Hb molecules in infants. It has two alpha and two gamma globin chains. Remnants of Hb F which is traceable in 1% of adult Caucasians may also change the results of Hb A 1C measurement. In the presence of Hb F, electrophoresis-based methods of detection of glycosylated Hb may not be reliable; as Hb A 1C and Hb F have similar electrical charges, and it is difficult to separate them through these techniques. Affinity chromatography is an alternative approach, giving a more accurate result. In a report of two diabetic patients with high levels of Hb F, the results of Hb A 1C by agarose gel electrophoresis were higher than expected ones, but through affinity chromatography method the results were wellmatched with patients' blood glucose levels [11] .
Hb A 1C measurement by HPLC method may also be doubtful in the presence of some types of hemoglobinopathies. In 43 diabetic patients carrying hemoglobinopathy of one type or another, Nasir and colleagues compared the results of measurement of Hb A 1C by two different methods -HPLC and immunoassay [24] . Even in patients with Hb F content above 10%, the results for Hb A 1C by the two methods were similar; however in Hb E patients, Hb A 1C measurement by HPLC had lower results than immunoassay method [12] . The study of Higgins and colleagues, however, reached a different conclusion. They demonstrated in cases with Hb F below 8%, immunologic and HPLC methods were both reliable and the differences negligible, but with Hb F above 10% and 20%, there were meaningful differences of 1% and 2% respectively, for the measurement of Hb A 1C by two methods [25] .
In patients with thalassemia intermedia, who do not receive regular blood transfusion and in particular are recipients of hydroxyl urea treatment, Hb F may reach to 98% of the total amount of Hb. In patients afflicted by "hereditary persistence of Hb F", Hb F content may have accumulation of 10% to 100% of the total Hb. In such cases, plasma glucose estimation based on measurement of Hb A 1C may not be accurate and alternative approaches such as evaluation of serum fructosamine are applicable [26] .
In brief, measurement of Hb A 1C in patients with thalassemia may lead to an unreliable result, as in one hand Hb F acts as an interfering factor and on the other hand patients with beta thalassemia have reduced or no synthesis of beta globin chain -the binding site of glucose molecule -to form Hb A 1C . Reduced production of beta globin chain leads to remarkable decrease in Hb A 1C synthesis.
In Thailand, Sridama et al examined 19 thalassemia patients suffering from diabetes. 18 cases had Hb A 1C results non-correlative to their fasting blood glucose levels. Fructosamine test also showed to be unreliable, as 6 cases had higher and one person lower results than expected ones -based on glucose content. They concluded in patients with abnormal hemoglobins or hemolytic disorders, none of these tests are reliable and have to be interpreted along with other related markers [21] . This finding is different from our results. It seems that frequent blood transfusion and in turn increased amount of mature Hb A and low levels of Hb F in our patients would be the main explanation for such discrepancy. In our study, Hb A 1C levels in diabetic patients with thalassemia showed a correlation with blood glucose content. We found a similar correlation with fructosamine, too. Examined patients were all patients with beta thalassemia major-subjects to frequent blood transfusion. These patients do not have bone marrow hematopoiesis activity and Hb F is in a negligible range [12] . This eliminates an important interfering factor in accurate measurement of Hb A 1C . Fresh blood is a natural source of Hb A, and thus through regular blood transfusion, adequate amounts of beta globin chains will be available for binding to glucose molecules. These facts may explain the results achieved in the current study.
CONCLUSION
The results of current study demonstrated that in patients with thalassemia major who are subject to frequent blood transfusion, laboratory examination of Hb A 1C level in blood serum is an acceptable approach to approximately calculate the amount of blood glucose storage within the past few months. Measurement of serum fructosamine is also applicable in these patients and may estimate blood glucose content for the shorter period of time. Both methods can be used 
